Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02473731 · ClinicalTrials.gov registry record · Phase 1
A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
A Phase 1 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02473731 is a Phase 1 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT02473731, a Phase 1 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the activity and safety of KTN3379 in head and neck cancer patients and to explore downstream molecular pathways to identify tumor response and resistance mechanisms by evaluating various biomarkers before and after treatment.
Interventions
- BIOLOGICAL KTN3379
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02473731
The ClinicalTrials.gov registry entry for NCT02473731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KTN3379 is the first listed.
NCT02473731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02473731 about?
NCT02473731 is a clinical study titled "A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients". The purpose of this study is to evaluate the activity and safety of KTN3379 in head and neck cancer patients and to explore downstream molecular pathways to identify tumor response and resistance mechanisms by evaluating various biomarkers before and after treatment.
What is the current status of trial NCT02473731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-10. Estimated completion is 2016-10-10.
What interventions are being tested in trial NCT02473731?
The interventions under investigation include: KTN3379 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02473731?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.